2022
DOI: 10.5056/jnm22012
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider

Abstract: published online; they have not yet been assigned to a journal issue. When these articles are published in an issue, they will be removed. Online First articles are copy-edited, typeset and approved by the authors before publication.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
11
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(11 citation statements)
references
References 36 publications
(35 reference statements)
0
11
0
Order By: Relevance
“…The therapeutic impact of probiotics on glycaemic control has been the subject of various investigations in humans. Recent clinical studies have produced encouraging outcomes, which emphasize the necessity of a thorough systematic review and meta-analysis of these results ( Markowiak and Ślizewska, 2017 ; Kim et al, 2019 ; Dudek-Wicher et al, 2020 ; Montassier et al, 2021 ; Mullish et al, 2021 ; Quigley, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…The therapeutic impact of probiotics on glycaemic control has been the subject of various investigations in humans. Recent clinical studies have produced encouraging outcomes, which emphasize the necessity of a thorough systematic review and meta-analysis of these results ( Markowiak and Ślizewska, 2017 ; Kim et al, 2019 ; Dudek-Wicher et al, 2020 ; Montassier et al, 2021 ; Mullish et al, 2021 ; Quigley, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…To avoid these problems in probiotic clinical trials, experts recommend selecting an appropriate research design in advance by considering the confounding factors above. 6 Although a parallel design is considered gold standards, a crossover design may reveal more accurate results if underlying gut microbiota is the main determining factor for the effectiveness of probiotics. 6 , 7 However, the crossover design is discouraged for the unknown carry-over effect of probiotics.…”
mentioning
confidence: 99%
“… 6 Although a parallel design is considered gold standards, a crossover design may reveal more accurate results if underlying gut microbiota is the main determining factor for the effectiveness of probiotics. 6 , 7 However, the crossover design is discouraged for the unknown carry-over effect of probiotics. 6 For this issue, Tremblay’s study 4 provided valuable insights that determining the optimal washout period for each study by considering both probiotic strain and the host-specific parameters is ideal, rather than having a 2-5-week washout period without rationale.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…The possibility to influence the homeostasis of neuroactive molecules such as 5-HT and GABA by means of microbiota-based treatment to attenuate gut and central nervous system symptoms related to IBS, has been extensively described in the review by Chen et al, which underlines the potential of dopamine and histamine as additional amine neurotransmitters that have received limited attention until now (4). However, manipulation of the indigenous microbiota has been shown to be an effective approach primarily on animal-based investigations since clinical evidence is still quite poor with variable results on disease outcomes mainly due to patient heterogeneity (5). Neuroendocrine signals involving hormones, such as sex steroids, along the microbiota-gut brain axis may also have a pathogenetic role in IBS and contribute to the sexual dimorphism, which represents a main feature of IBS, with females more prone to develop the disorder with respect to males.…”
mentioning
confidence: 99%